Catalent, Inc. Common Stock (CTLT)

Competitors to Catalent, Inc. Common Stock (CTLT)

Alcami Corporation

Alcami Corporation is a mid-sized player in the CDMO market, providing integrated solutions for drug development and manufacturing. In comparison to Catalent, which is larger and has a more comprehensive range of services and capabilities, Alcami can focus on personalized service and niche markets that allow for agility and adaptability. While Alcami offers competitive pricing and tailored solutions, Catalent's scale and extensive global network generally provide greater reliability and capacity in fulfilling large-scale orders.

Boehringer Ingelheim

Boehringer Ingelheim operates both as a pharmaceutical developer and as a contract manufacturer. While Catalent primarily offers CDMO services, Boehringer's dual-operation model enhances its capacity for internal R&D and manufacturing, giving it a competitive edge in innovation and process efficiency. The ability to keep their pipeline aligned with manufacturing capabilities positions Boehringer favorably, although it may not compete directly in all areas where Catalent operates.

Lonza Group AG

Lonza and Catalent are major players in the contract development and manufacturing organizations (CDMO) sector, specializing in biopharmaceuticals. Lonza has established itself in the cell and gene therapy domains, enjoying strong customer relationships and high industry standards that enhance its reputation. This specialization gives Lonza an advantage in attracting partnerships within cutting-edge biotech, while Catalent continues to expand its capabilities in different modalities and a broader client base.

Piramal Pharma Solutions

Piramal Pharma Solutions focuses on drug discovery, development, and manufacturing services, similar to Catalent. However, Piramal has a robust footprint in sterile manufacturing and injectables, which positions it strongly against Catalent in those niche areas. As Catalent continues to increase its presence in other areas, including oral solid dose forms, competition remains tight, but Piramal's specialization in injectables can provide an advantage in that segment.

Thermo Fisher Scientific Inc. 

Thermo Fisher Scientific and Catalent both operate in the biopharmaceutical contract development and manufacturing space. Thermo Fisher has a broader portfolio, including analytical instruments and laboratory services, allowing it to leverage its integrated solutions to attract clients seeking comprehensive services from discovery to distribution. This extensive network gives Thermo Fisher a competitive edge, especially in innovation and large-scale biomanufacturing.